Cargando…

The Expression of TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Can Be Controlled by the Antioxidant Orchestrator NRF2 in Human Carcinoma Cells

Hyperactivation of the KEAP1-NRF2 axis is a common molecular trait in carcinomas from different origin. The transcriptional program induced by NRF2 involves antioxidant and metabolic genes that render cancer cells more capable of dealing with oxidative stress. The TP53-Induced Glycolysis and Apoptos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon-Molas, Helga, Sánchez-de-Diego, Cristina, Navarro-Sabaté, Àurea, Castaño, Esther, Ventura, Francesc, Bartrons, Ramon, Manzano, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836827/ https://www.ncbi.nlm.nih.gov/pubmed/35163828 http://dx.doi.org/10.3390/ijms23031905

Ejemplares similares

TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Is Upregulated in Lymphocytes Stimulated with Concanavalin A
por: Simon-Molas, Helga, et al.
Publicado: (2021)

Fructose 2,6-Bisphosphate in Cancer Cell Metabolism
por: Bartrons, Ramon, et al.
Publicado: (2018)

Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide
por: Maurer, Gabriele D., et al.
Publicado: (2019)

TIGAR, TIGAR, burning bright
por: Lee, Pearl, et al.
Publicado: (2014)

The in vivo function of the p53 target gene TIGAR
por: Cheung, Eric C, et al.
Publicado: (2012)

The Regulation of TIGAR
por: Lee, Pearl, et al.
Publicado: (2014)

p53- and p73-independent activation of TIGAR expression in vivo
por: Lee, P, et al.
Publicado: (2015)

NEURL4 regulates the transcriptional activity of tumor suppressor protein p53 by modulating its oligomerization
por: Cubillos-Rojas, Monica, et al.
Publicado: (2017)

TP53 mutation hits energy metabolism and increases glycolysis in breast cancer
por: Harami-Papp, Hajnalka, et al.
Publicado: (2016)

MiR-652-5p elevated glycolysis level by targeting TIGAR in T-cell acute lymphoblastic leukemia
por: Liu, Shan, et al.
Publicado: (2022)

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS(Q61)-mutated melanomas to targeted therapy
por: McGrail, Kimberley, et al.
Publicado: (2022)

Regulation of the MDM2‐p53 pathway by the ubiquitin ligase HERC2
por: García‐Cano, Jesús, et al.
Publicado: (2019)

The in vivo function of TIGAR, a p53 target gene that regulates glucose metabolism
por: Cheung, Eric, et al.
Publicado: (2014)

Insights from the p53 induced TIGAR protein 2 in the glycolytic pathway model
por: Jahoor Alam, Mohammad
Publicado: (2022)

Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop via NRF2 in cancer therapeutic resistance
por: Wang, Hong, et al.
Publicado: (2022)

TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells
por: WONG, ELAINE YUE LING, et al.
Publicado: (2015)

Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients
por: AL-KHAYAL, KHAYAL, et al.
Publicado: (2016)

The role of TIGAR in nervous system diseases
por: Huang, Bei, et al.
Publicado: (2022)

TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia
por: Qian, Sixuan, et al.
Publicado: (2016)

TP53-induced glycolysis and apoptosis regulator is indispensable for mitochondria quality control and degradation following damage
por: Feng, Jing, et al.
Publicado: (2018)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TIGAR Is Required for Efficient Intestinal Regeneration and Tumorigenesis
por: Cheung, Eric C., et al.
Publicado: (2013)

Oral Lichen Planus and Mutated TP53—A Road to Cancer?
por: Holbrook, William Peter, et al.
Publicado: (2022)

Down‐regulation of TFAM increases the sensitivity of tumour cells to radiation via p53/TIGAR signalling pathway
por: Jiang, Xu, et al.
Publicado: (2019)

Modulation of intracellular ROS levels by TIGAR controls autophagy
por: Bensaad, Karim, et al.
Publicado: (2009)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53-induced glycolysis and apoptosis regulator alleviates hypoxia/ischemia-induced microglial pyroptosis and ischemic brain damage
por: Tan, Lan-Lan, et al.
Publicado: (2020)

TIGAR induces p53-mediated cell-cycle arrest by regulation of RB–E2F1 complex
por: Madan, E, et al.
Publicado: (2012)

Inhibition of TIGAR Increases Exogenous p53 and Cisplatin Combination Sensitivity in Lung Cancer Cells by Regulating Glycolytic Flux
por: Fu, Jiaying, et al.
Publicado: (2022)

High Glucose Activates Prolyl Hydroxylases and Disrupts HIF-α Signaling via the P53/TIGAR Pathway in Cardiomyocyte
por: Chen, Jian-Xiong, et al.
Publicado: (2023)

The ubiquitin ligase HERC1 regulates cell migration via RAF-dependent regulation of MKK3/p38 signaling
por: Pedrazza, Leonardo, et al.
Publicado: (2020)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Higher plasma concentration of TP53-induced glycolysis and apoptosis regulator is associated with a lower risk of colorectal cancer metastasis
por: Lin, Lin, et al.
Publicado: (2018)

Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells
por: Norden, Elisabeth, et al.
Publicado: (2019)

p53‐TP53‐Induced Glycolysis Regulator Mediated Glycolytic Suppression Attenuates DNA Damage and Genomic Instability in Fanconi Anemia Hematopoietic Stem Cells
por: Li, Xue, et al.
Publicado: (2019)

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms
por: Moore, Ellen C., et al.
Publicado: (2018)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hdjerrgdl3gb6l1blb8j0nbftk